Fundraising Fox
Alchemab
Founded 2019 · 73 employees on LinkedIn · 10 known investors
Find your way into Alchemab
Sign up to see every warm intro you have to Alchemab
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Alchemab team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals. The company develops protective antibody therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology.
Founders & leadership
Investors · 10
How we know: RA Capital's portfolio page · the company's own site · funding news · Not right? Tell us
How we know: SV Health Investors's portfolio page · the company's own site · a partner's Signal profile · funding news · Not right? Tell us
How we know: the company's own site · funding news · Not right? Tell us
How we know: Dementia Discovery Fund's portfolio page · funding news · Not right? Tell us
How we know: Lightstone Ventures's portfolio page · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Ono Venture Investment, Inc.'s portfolio page · funding news · Not right? Tell us
How we know: funding news · eu-startups.com · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Founder mafia
3 people who came through Alchemab went on to found or lead other companies.
In the news
Frequently asked questions
- What does Alchemab do?
- Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals. The company develops protective antibody therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology.
- Who are Alchemab's investors?
- Alchemab's investors include RA Capital, SV Health Investors, DCVC Bio, Dementia Discovery Fund, Lightstone Ventures, Ono Venture Investment, Inc., British Business Bank, British Patient Capital and 2 more.